阿司匹林抵抗的研究进展及中西医结合研究方向

发布时间：2018-04-04 11:51

本文选题：阿司匹林抵抗　切入点：单核苷酸多态性　出处：《中国中西医结合杂志》2010年06期

【摘要】：阿司匹林是最经典的抗血小板药物,以其优异的效价比,在人类心脑血管病防治方面发挥着重要作用,然而其抗血小板作用个体差异很大,约25%～40%存在阿司匹林抵抗(aspirin resistance,AR),严重影响了其干预效果,已成为一个备受关注的临床问题。笔者认为,从长期服用抗血小板剂量阿司匹林的心脑血管病患者中筛选AR患者,从线粒体基因组单核苷酸多态性(MtSNP)寻找其基因差异位点,可为临床及早预测AR并制定合理干预策略奠定基础;同时运用均匀设计优化方法 ,对AR患者的血小板进行体外干预,探索防治AR抗血小板中药的最佳配伍组合和配比关系,发挥中药复方多靶点干预特点,可为临床研发防治AR的有效复方中药制剂提供新的思路。
[Abstract]:Aspirin is the most classical antiplatelet drug. With its excellent titer ratio, aspirin plays an important role in the prevention and treatment of human cardiovascular and cerebrovascular diseases.About 25% of aspirin resists aspirin resistance to aspirin resistance, which seriously affects the effect of intervention and has become a clinical issue of great concern.The authors suggested that AR patients were screened from patients with cardiovascular and cerebrovascular diseases who took long-term antiplatelet aspirin, and their gene difference sites were found from mitochondrial genome single nucleotide polymorphisms (mtSNPs).It can lay a foundation for early prediction of AR and rational intervention strategy in clinic, at the same time, it can use uniform design optimization method to intervene platelet of AR patients in vitro, and to explore the best combination and proportion of anti-platelet Chinese medicine for prevention and treatment of AR.Giving full play to the characteristics of multi-target intervention of Chinese herbal compound can provide a new idea for clinical research and development of effective compound Chinese medicine preparation for AR prevention and treatment.
【作者单位】：中日友好医院全国中西医结合心血管病中心;
【分类号】：R2-031

【参考文献】